TY  - JOUR
T1  - Targeted therapy for metastatic renal cell carcinoma: Current treatment and future directions
A1  - Noura Majid
A1  - Nabil Ismaili
A1  - Mounia Amzerin
A1  - Hassan Errihani
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2013
VL  - 2
IS  - 3
DO  - 10.4103/2278-0513.119257
SP  - 195
EP  - 201
N2  - Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 3% of all adult cancers. The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being a predominantly cytokine-based treatment to the use of targeted agents, which include Sorafenib, Sunitinib, Bevacizumab, Temsirolimus, Everolimus, Pazopanib, Axitinib, and most recently Tivozanib. Despite these advances mRCC remains a major health problem. Additional studies are needed to optimize the use of these agents in both advanced and early stage disease, either in combination or sequentially. In addition the development of biomarkers should be a priority in order to guide rational tailored development of emerging agents. This literature review was conducted using PubMed, Medline, and Cochrane databases for articles published until January 2013. Abstracts from relevant meeting of the American Society of Clinical Oncology and the European society of medical oncology were also included.
UR  - https://ccij-online.org/article/targeted-therapy-for-metastatic-renal-cell-carcinoma:-current-treatment-and-future-directions-115
ER  -